ketamine has been researched along with Encephalopathy, Toxic in 32 studies
Ketamine: A cyclohexanone derivative used for induction of anesthesia. Its mechanism of action is not well understood, but ketamine can block NMDA receptors (RECEPTORS, N-METHYL-D-ASPARTATE) and may interact with sigma receptors.
ketamine : A member of the class of cyclohexanones in which one of the hydrogens at position 2 is substituted by a 2-chlorophenyl group, while the other is substituted by a methylamino group.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Evidence suggests that some aspects of schizophrenia can be induced in healthy volunteers through acute administration of the non-competitive NMDA-receptor antagonist, ketamine." | 9.16 | Performance on a probabilistic inference task in healthy subjects receiving ketamine compared with patients with schizophrenia. ( Almahdi, B; Averbeck, BB; Brandner, B; Collier, T; Cregg, R; Evans, S; Shergill, SS; Sohanpal, I; Sultan, P, 2012) |
| "A 44-year-old man with treated neurosyphilis presented with subclinical status epilepticus (SE) refractory to intravenous high-dose lorazepam, phenytoin, and valproic acid over 4 days." | 7.72 | Ketamine for refractory status epilepticus: a case of possible ketamine-induced neurotoxicity. ( Lerner, AJ; Maddux, BN; Sagar, SM; Suarez, JI; Ubogu, EE; Werz, MA, 2003) |
| "Evidence suggests that some aspects of schizophrenia can be induced in healthy volunteers through acute administration of the non-competitive NMDA-receptor antagonist, ketamine." | 5.16 | Performance on a probabilistic inference task in healthy subjects receiving ketamine compared with patients with schizophrenia. ( Almahdi, B; Averbeck, BB; Brandner, B; Collier, T; Cregg, R; Evans, S; Shergill, SS; Sohanpal, I; Sultan, P, 2012) |
| "Our results demonstrated that GA, induced by intravenous ketamine or inhalational sevoflurane, disturbed iron homeostasis and caused iron overload in both in vitro hippocampal neuron culture and in vivo hippocampus." | 3.96 | Iron overload contributes to general anaesthesia-induced neurotoxicity and cognitive deficits. ( Cao, Y; Li, H; Li, K; Wu, J; Yang, JJ; Yang, S; Zhao, H, 2020) |
| "Ketamine, though widely used in pediatric anesthesia, may induce cortical neurotoxicity in young patients." | 3.91 | MicroRNA-107 regulates anesthesia-induced neural injury in embryonic stem cell derived neurons. ( Gao, F; Huang, FY; Jiang, JD; You, MZ; Zheng, T; Zheng, XC, 2019) |
| "A 44-year-old man with treated neurosyphilis presented with subclinical status epilepticus (SE) refractory to intravenous high-dose lorazepam, phenytoin, and valproic acid over 4 days." | 3.72 | Ketamine for refractory status epilepticus: a case of possible ketamine-induced neurotoxicity. ( Lerner, AJ; Maddux, BN; Sagar, SM; Suarez, JI; Ubogu, EE; Werz, MA, 2003) |
| "We report a case of opioid-induced neurotoxicity (OIN) in an actively dying hospice patient, its reversal and improved analgesia that followed opioid dosage reduction made possible after addition of IV ketamine." | 2.53 | Intravenous Ketamine for Rapid Opioid Dose Reduction, Reversal of Opioid-Induced Neurotoxicity, and Pain Control in Terminal Care: Case Report and Literature Review. ( Bradshaw, YS; Carr, DB; Winegarden, J, 2016) |
| " This article discusses the limitations of the published animal research, the challenges in extrapolating such data to humans, the need for further animal and human investigations, and the potential adverse effect on current clinical practice that might result, should the use of ketamine be restricted or the drug removed from the market." | 2.45 | Ketamine and neurotoxicity: clinical perspectives and implications for emergency medicine. ( Coté, CJ; Green, SM, 2009) |
| "Ketamine is a widely used drug in pediatric anesthesia practice, acting primarily through the blockade of the N-methyl-D-aspartate (NMDA) type of glutamate receptors." | 2.44 | Effects of ketamine on the developing central nervous system. ( Gascon, E; Kiss, JZ; Vutskits, L, 2007) |
| "Ketamine is a kind of anesthetic broadly applied in clinic." | 1.62 | MiRNA-429 alleviates ketamine-induced neurotoxicity through targeting BAG5. ( Bian, W; Fan, X; Li, J; Liu, M; Wang, Y, 2021) |
| "Ketamine is an anesthetic and analgesic drug widely used in clinical anesthesia." | 1.56 | Ketamine exerts neurotoxic effects on the offspring of pregnant rats via the Wnt/β-catenin pathway. ( Chang, T; Gao, L; Liu, W; Wang, Q; Zhang, X; Zhao, J, 2020) |
| " In this study, we investigated the toxic effect of ketamine on neurons differentiated from hESCs." | 1.38 | Ketamine induces toxicity in human neurons differentiated from embryonic stem cells via mitochondrial apoptosis pathway. ( Bai, X; Bosnjak, ZJ; Canfield, S; Corbett, JA; Kikuchi, C; Muravyeva, MY; Wells, CW; Yan, Y, 2012) |
| "The ketamine pretreatment attenuated the lidocaine-induced damage in the CA3 hippocampal region and the basolateral amygdala." | 1.35 | Ketamine prevents lidocaine-caused neurotoxicity in the CA3 hippocampal and basolateral amygdala regions of the brain in adult rats. ( Cano-Europa, E; Lopez-Galindo, GE; Ortiz-Butron, R, 2008) |
| "Ketamine is a widely used pediatric anesthetic recently reported (C." | 1.32 | Developmental neurotoxicity of ketamine: morphometric confirmation, exposure parameters, and multiple fluorescent labeling of apoptotic neurons. ( Davis, H; Faustino, PJ; Grunberg, N; Hanig, JP; Lester, D; Pine, PS; Scallet, AC; Schmued, LC; Sistare, F; Slikker, W, 2004) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 12 (37.50) | 29.6817 |
| 2010's | 15 (46.88) | 24.3611 |
| 2020's | 5 (15.63) | 2.80 |
| Authors | Studies |
|---|---|
| Li, M | 1 |
| Xue, Y | 1 |
| Ilahi, Z | 1 |
| Janardhan, S | 1 |
| Dave, M | 1 |
| Khariton, M | 1 |
| Feuer, P | 1 |
| Venkataraman, A | 1 |
| Romanos-Sirakis, E | 1 |
| Zhang, X | 1 |
| Zhao, J | 1 |
| Chang, T | 1 |
| Wang, Q | 1 |
| Liu, W | 1 |
| Gao, L | 1 |
| Wu, J | 1 |
| Yang, JJ | 1 |
| Cao, Y | 1 |
| Li, H | 1 |
| Zhao, H | 1 |
| Yang, S | 1 |
| Li, K | 1 |
| Fan, X | 1 |
| Bian, W | 1 |
| Liu, M | 1 |
| Li, J | 1 |
| Wang, Y | 1 |
| Liao, YH | 1 |
| Wang, YH | 1 |
| Sun, LH | 1 |
| Deng, WT | 1 |
| Lee, HT | 1 |
| Yu, L | 2 |
| Jiang, JD | 1 |
| Zheng, XC | 1 |
| Huang, FY | 1 |
| Gao, F | 1 |
| You, MZ | 1 |
| Zheng, T | 1 |
| Zhao, X | 1 |
| Shu, F | 1 |
| Wang, X | 1 |
| Wang, F | 1 |
| Wu, L | 1 |
| Li, L | 1 |
| Lv, H | 1 |
| Liu, JR | 1 |
| Baek, C | 1 |
| Han, XH | 1 |
| Shoureshi, P | 1 |
| Soriano, SG | 1 |
| Dong, C | 1 |
| Anand, KJ | 3 |
| Yan, J | 1 |
| Jiang, H | 1 |
| Gewandter, JS | 1 |
| Mohile, SG | 1 |
| Heckler, CE | 1 |
| Ryan, JL | 1 |
| Kirshner, JJ | 1 |
| Flynn, PJ | 1 |
| Hopkins, JO | 1 |
| Morrow, GR | 1 |
| Xu, H | 1 |
| Zhang, J | 1 |
| Zhou, W | 1 |
| Feng, Y | 1 |
| Teng, S | 1 |
| Song, X | 1 |
| Winegarden, J | 1 |
| Carr, DB | 1 |
| Bradshaw, YS | 1 |
| Wang, C | 2 |
| Liu, F | 1 |
| Patterson, TA | 1 |
| Paule, MG | 1 |
| Slikker, W | 3 |
| Green, SM | 1 |
| Coté, CJ | 1 |
| Lopez-Galindo, GE | 1 |
| Cano-Europa, E | 1 |
| Ortiz-Butron, R | 1 |
| van Amsterdam, JG | 2 |
| Brunt, TM | 2 |
| McMaster, MT | 2 |
| Niesink, RJ | 1 |
| Evans, S | 1 |
| Almahdi, B | 1 |
| Sultan, P | 1 |
| Sohanpal, I | 1 |
| Brandner, B | 1 |
| Collier, T | 1 |
| Shergill, SS | 1 |
| Cregg, R | 1 |
| Averbeck, BB | 1 |
| Turner, CP | 1 |
| Gutierrez, S | 1 |
| Liu, C | 1 |
| Miller, L | 1 |
| Chou, J | 1 |
| Finucane, B | 1 |
| Carnes, A | 1 |
| Kim, J | 1 |
| Shing, E | 1 |
| Haddad, T | 1 |
| Phillips, A | 1 |
| Bosnjak, ZJ | 1 |
| Yan, Y | 1 |
| Canfield, S | 1 |
| Muravyeva, MY | 1 |
| Kikuchi, C | 1 |
| Wells, CW | 1 |
| Corbett, JA | 1 |
| Bai, X | 1 |
| Niesink, R | 1 |
| van Noorden, MS | 1 |
| van den Brink, W | 1 |
| Ubogu, EE | 1 |
| Sagar, SM | 1 |
| Lerner, AJ | 1 |
| Maddux, BN | 1 |
| Suarez, JI | 1 |
| Werz, MA | 1 |
| Nakao, S | 1 |
| Nagata, A | 1 |
| Masuzawa, M | 1 |
| Miyamoto, E | 1 |
| Yamada, M | 1 |
| Nishizawa, N | 1 |
| Shingu, K | 1 |
| Scallet, AC | 1 |
| Schmued, LC | 1 |
| Grunberg, N | 1 |
| Faustino, PJ | 1 |
| Davis, H | 1 |
| Lester, D | 1 |
| Pine, PS | 1 |
| Sistare, F | 1 |
| Hanig, JP | 1 |
| Himmelseher, S | 1 |
| Durieux, ME | 1 |
| Vutskits, L | 1 |
| Gascon, E | 1 |
| Kiss, JZ | 1 |
| Bhutta, AT | 1 |
| Venkatesan, AK | 1 |
| Rovnaghi, CR | 1 |
| Majewski-Tiedeken, CR | 1 |
| Rabin, CR | 1 |
| Siegel, SJ | 1 |
| Ke, JJ | 1 |
| Chen, HI | 1 |
| Jen, CJ | 1 |
| Kuo, YM | 1 |
| Cherng, CG | 1 |
| Tsai, YP | 1 |
| Ho, MC | 1 |
| Tsai, CW | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Assessment of Topical Treatment Response With Amitriptyline and Ketamine: Combination Trial in Chemotherapy Peripheral Neuropathy (ATTRACT-CPN)[NCT00471445] | Phase 3 | 462 participants (Actual) | Interventional | 2007-10-31 | Completed | ||
| Oral Ketamine for Control of Chronic Pain in Children[NCT01369680] | Phase 1 | 12 participants (Actual) | Interventional | 2011-05-31 | Completed | ||
| A Pilot Study to Assess the Efficacy of Subanesthetic Doses of IV Ketamine in the Treatment Drug Resistant Epilepsy[NCT05019885] | Phase 2 | 6 participants (Anticipated) | Interventional | 2022-08-26 | Recruiting | ||
| Anesthesia Exposure and Neurodevelopment in Infants and Children: Pediatric Anesthesia & NeuroDevelopment (PANDA) Study[NCT00881764] | 369 participants (Actual) | Observational | 2009-05-31 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
"Cancer survivors who completed chemotherapy at least 1 month prior and had Chemotherapy Induced Peripheral Neuropathy (CIPN) (greater than or equal to 4 out of 10) were enrolled. CIPN was assessed using average scores from a 7-day daily diary that asks patients to rate the average pain, numbness, or tingling in their hands and feet over the past 24 hours on an 11-point numeric rating scale at baseline and 6 weeks post intervention. CIPN ranges from 0 (no pain) to 10 (worst possible pain)." (NCT00471445)
Timeframe: Week 6 - Baseline
| Intervention | units on a scale (Mean) | |
|---|---|---|
| Baseline | Week 6 | |
| Ketamine/Amitriptyline NP-H Cream | 6.55 | 4.93 |
| Placebo Cream | 6.47 | 5.19 |
"Baseline neurocognitive testing will be done before study drug is given. Subjects will be reassessed for any changes in neurocognitive scores at end of dosing (week 2) and at three weeks off study drug (week 14). Significant changes were measured at week 14 compared to baseline. Week 2 was measured to inform future studies.~The neurocognitive scores are standardized scores with a mean of 100; low scores correlate with low neurocognitive function, while high scores correlate with high function. A significant change is defined as greater than or equal to 10% decrease in scores." (NCT01369680)
Timeframe: At 14 weeks
| Intervention | participants (Number) |
|---|---|
| Ketamine 0.25 mg/kg/Dose | 0 |
| Ketamine 0.5 mg/kg/Dose | 0 |
| Ketamine 1 mg/kg/Dose | 0 |
| Ketamine 1.5 mg/kg/Dose | 0 |
Pharmacokinetic testing will be done during chronic ketamine administration on subjects consenting to additional testing one week into study drug administration. This is to further describe the activity of ketamine in the blood of children when administered chronically and to enable comparison of any clinical effect or toxicity with steady state levels of ketamine in children. (NCT01369680)
Timeframe: At week 1
| Intervention | ng/mL (Mean) |
|---|---|
| Ketamine 0.25 mg/kg/Dose | 37.5 |
| Ketamine 0.5 mg/kg/Dose | 135 |
| Ketamine 1 mg/kg/Dose | 250 |
According to CTCae any dose causing grade 2 or worse toxicity will be an untolerated dose. Tolerability is defined as ability to take the medication for 2 weeks without having a grade 2 or worse toxicity. (NCT01369680)
Timeframe: Up to 2 weeks
| Intervention | participants (Number) |
|---|---|
| Ketamine 0.25 mg/kg/Dose | 3 |
| Ketamine 0.5 mg/kg/Dose | 3 |
| Ketamine 1 mg/kg/Dose | 3 |
| Ketamine 1.5 mg/kg/Dose | 1 |
"Subjects will be assessed for clinically significant change in pain scores during and after study drug administration. Significant change in pain scores were determined at week 2, though week 14 scores were collected as well.~Participants with a 2 point (or greater) decrease in pain scores compared to baseline were considered to have responded. The NRS scale was used, the scale ranges from 0-10, with 10 being the most pain." (NCT01369680)
Timeframe: Week 2
| Intervention | participants (Number) |
|---|---|
| Ketamine 0.25 mg/kg/Dose | 3 |
| Ketamine 0.5 mg/kg/Dose | 0 |
| Ketamine 1 mg/kg/Dose | 2 |
| Ketamine 1.5 mg/kg/Dose | 0 |
12 reviews available for ketamine and Encephalopathy, Toxic
| Article | Year |
|---|---|
Developmental neurotoxicity of ketamine in pediatric clinical use.
Topics: Analgesics; Apoptosis; Brain; Cell Differentiation; Female; Humans; Infant, Newborn; Infant, Prematu | 2013 |
Dual effects of ketamine: neurotoxicity versus neuroprotection in anesthesia for the developing brain.
Topics: Anesthetics, Dissociative; Animals; Brain; Child, Preschool; Developmental Disabilities; Excitatory | 2014 |
Intravenous Ketamine for Rapid Opioid Dose Reduction, Reversal of Opioid-Induced Neurotoxicity, and Pain Control in Terminal Care: Case Report and Literature Review.
Topics: Adult; Analgesics, Opioid; Anesthetics, Dissociative; Hospice Care; Humans; Infusions, Intravenous; | 2016 |
Relationship between ketamine-induced developmental neurotoxicity and NMDA receptor-mediated calcium influx in neural stem cell-derived neurons.
Topics: Anesthetics, Dissociative; Animals; Calcium; Excitatory Amino Acid Antagonists; Humans; Ketamine; Ne | 2017 |
Ketamine and neurotoxicity: clinical perspectives and implications for emergency medicine.
Topics: Anesthetics, Dissociative; Animals; Apoptosis; Child; Emergency Medicine; Humans; Ketamine; Nerve De | 2009 |
Possible long-term effects of γ-hydroxybutyric acid (GHB) due to neurotoxicity and overdose.
Topics: Alcoholism; Anesthetics; Anesthetics, Dissociative; Animals; Central Nervous System Depressants; Cog | 2012 |
[Cognitive impairment due to intensive use and overdoses of gammahydroxybutyric acid (GHB)].
Topics: Cognition; Coma; Drug Overdose; Ethanol; Humans; Hydroxybutyrates; Illicit Drugs; Ketamine; Neurotox | 2012 |
[NMDA receptor antagonist neurotoxicity and psychotomimetic activity].
Topics: Anesthetics, Dissociative; Animals; Cerebral Cortex; Dizocilpine Maleate; Drug Synergism; GABA Modul | 2003 |
Revising a dogma: ketamine for patients with neurological injury?
Topics: Anesthetics, Dissociative; Cerebrovascular Circulation; Critical Care; Excitatory Amino Acid Antagon | 2005 |
Effects of ketamine on the developing central nervous system.
Topics: Anesthetics, Dissociative; Animals; Brain; Central Nervous System; Humans; Ketamine; Neurotoxicity S | 2007 |
Anaesthetic neurotoxicity in rodents: is the ketamine controversy real?
Topics: Anesthetics, Dissociative; Animals; Brain Injuries; Cell Death; Disease Models, Animal; Ketamine; Ne | 2007 |
Strategies and experimental models for evaluating anesthetics: effects on the developing nervous system.
Topics: Anesthetics; Animals; Animals, Newborn; Behavior, Animal; Biomedical Research; Cell Death; Disease M | 2008 |
2 trials available for ketamine and Encephalopathy, Toxic
| Article | Year |
|---|---|
A phase III randomized, placebo-controlled study of topical amitriptyline and ketamine for chemotherapy-induced peripheral neuropathy (CIPN): a University of Rochester CCOP study of 462 cancer survivors.
Topics: Administration, Topical; Adult; Aged; Amitriptyline; Antineoplastic Agents; Double-Blind Method; Fem | 2014 |
Performance on a probabilistic inference task in healthy subjects receiving ketamine compared with patients with schizophrenia.
Topics: Adult; Anesthetics, Dissociative; Antipsychotic Agents; Decision Making; Diagnostic and Statistical | 2012 |
18 other studies available for ketamine and Encephalopathy, Toxic
| Article | Year |
|---|---|
The upregulation of Nur77 decreases ketamine-induced hippocampal neurons toxicity in rats.
Topics: Animals; Apoptosis; bcl-2-Associated X Protein; Cytokines; Heme Oxygenase (Decyclizing); Hippocampus | 2021 |
Ketamine as an Adjunct for Treatment of Methotrexate-induced Neurotoxicity.
Topics: Child; Homocysteine; Humans; Ketamine; Methotrexate; Neurotoxicity Syndromes; Paresis | 2022 |
Ketamine exerts neurotoxic effects on the offspring of pregnant rats via the Wnt/β-catenin pathway.
Topics: Analgesics; Animals; beta Catenin; Cognitive Dysfunction; Down-Regulation; Female; Hippocampus; Keta | 2020 |
Iron overload contributes to general anaesthesia-induced neurotoxicity and cognitive deficits.
Topics: Anesthesia, General; Anesthetics, General; Animals; Hippocampus; Iron; Iron Overload; Ketamine; Male | 2020 |
MiRNA-429 alleviates ketamine-induced neurotoxicity through targeting BAG5.
Topics: Adaptor Proteins, Signal Transducing; Animals; Apoptosis; Dose-Response Relationship, Drug; Down-Reg | 2021 |
mGluR5 upregulation and the effects of repeated methamphetamine administration and withdrawal on the rewarding efficacy of ketamine and social interaction.
Topics: Animals; Dopamine; Excitatory Amino Acid Transporter 3; Hippocampus; Homer Scaffolding Proteins; Int | 2018 |
MicroRNA-107 regulates anesthesia-induced neural injury in embryonic stem cell derived neurons.
Topics: Anesthesia; Animals; Apoptosis; Brain Injuries; Brain-Derived Neurotrophic Factor; Cell Differentiat | 2019 |
Inhibition of microRNA-375 ameliorated ketamine-induced neurotoxicity in human embryonic stem cell derived neurons.
Topics: Anesthetics; Brain-Derived Neurotrophic Factor; Cell Differentiation; Cell Line; Human Embryonic Ste | 2019 |
Role of glycogen synthase kinase-3β in ketamine-induced developmental neuroapoptosis in rats.
Topics: Anesthetics, Dissociative; Animals; Animals, Newborn; Apoptosis; Brain; Caspase 3; Enzyme Activation | 2013 |
The role of miR-124 in modulating hippocampal neurotoxicity induced by ketamine anesthesia.
Topics: Animals; Animals, Newborn; Apoptosis; Disease Models, Animal; Hippocampus; In Vitro Techniques; Keta | 2015 |
Ketamine prevents lidocaine-caused neurotoxicity in the CA3 hippocampal and basolateral amygdala regions of the brain in adult rats.
Topics: Amygdala; Anesthetics, Local; Animals; Cell Count; Excitatory Amino Acid Antagonists; Hippocampus; K | 2008 |
Strategies to defeat ketamine-induced neonatal brain injury.
Topics: Anesthetics, Dissociative; Animals; Animals, Newborn; Apoptosis; Brain Injuries; Disease Models, Ani | 2012 |
Ketamine induces toxicity in human neurons differentiated from embryonic stem cells via mitochondrial apoptosis pathway.
Topics: Anesthetics, Dissociative; Antioxidants; Apoptosis; Cell Differentiation; Chromans; Cytochromes c; D | 2012 |
Ketamine for refractory status epilepticus: a case of possible ketamine-induced neurotoxicity.
Topics: Adult; Anticonvulsants; Atrophy; Brain; Electroencephalography; Excitatory Amino Acid Antagonists; H | 2003 |
Developmental neurotoxicity of ketamine: morphometric confirmation, exposure parameters, and multiple fluorescent labeling of apoptotic neurons.
Topics: Animals; Animals, Newborn; Apoptosis; Brain; Brain Chemistry; Dose-Response Relationship, Drug; Exci | 2004 |
Anesthetic neurotoxicity in newborns: should we change clinical practice?
Topics: Anesthetics; Anesthetics, Dissociative; Animals; Humans; Infant, Newborn; Ketamine; Nerve Degenerati | 2007 |
Ketamine exposure in adult mice leads to increased cell death in C3H, DBA2 and FVB inbred mouse strains.
Topics: Animals; Caspase 3; Cell Death; Cell Nucleus; Evoked Potentials; Excitatory Amino Acid Antagonists; | 2008 |
Mutual enhancement of central neurotoxicity induced by ketamine followed by methamphetamine.
Topics: 6-Cyano-7-nitroquinoxaline-2,3-dione; Anesthetics, Dissociative; Animals; Benzazepines; Body Tempera | 2008 |